FDA Accepts Krystal Biotech’s Filing For Genetic Skin Disorder Candidate Under Priority Review
[ad_1] The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s KRYS Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with…
Bluebird Secures FDA Nod For Genetic Blood Disease Candidate
[ad_1] The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s BLUE lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients…
Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage Study
[ad_1] Ventyx Biosciences VTYX announced positive data from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX958, a novel and selective allosteric TYK2 inhibitor.…
Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint
[ad_1] Aptinyx Inc. APTX announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate…
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate
[ad_1] The European Commission (EC) has granted marketing authorization for Argenx’s ARGX lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult patients with…